Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting

• Status: Unknown status
• Trial end date: 2019-12-15
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety and efficacy of low dosage of Terazosin in Carotid Artery Stenting

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Capital Medical University
• Collaborators: Beijing Anzhen Hospital; The Luhe Teaching Hospital of the Capital Medical University
• Treatments: Prazosin; Terazosin

Criteria

Inclusion Criteria:

1. Symptomatic or asymptomatic carotid artery stenosis. In symptomatic patients the degree of stenosis should more than 50% (Based on NASCET Criteria), in asymptomatic patients the degree of stenosis should more than 70% (Based on NASCET Criteria);

2. Tolerance to any of the study medications, including TZ, clopidogrel, aspirin and statins;

3. Hypertensive patients with or without oral antihypertensive drugs

4. Can cooperate with and complete brain MRI examination;

5. Stable vital signs, cardiopulmonary, liver and kidney function was no obvious abnormalities;

6. Has a negative pregnancy test within 7 days before randomization and no childbearing potential;

7. Stable vital sign, normal renal and hepatic functions;

8. Informed consent.

Exclusion Criteria:

1. Evolving stroke;

2. Hemorrhagic tendency；

3. Severe dementia or Prior major ipsilateral stroke, if likely to confound study endpoints;

4. Chronic atrial fibrillation or any other Cardiogenic emboli source disease;

5. Myocardial infarction within previous 30 days;

6. Spontaneous Intracerebral Hemorrhage within the past 180 days, Hemorrhagic conversion of an ischemic stroke within the past 60 days or recent (<7 days) large area cerebral infarction has a hemorrhagic conversion tendence;

7. Any conditions that hampers proper angiographic assessment or makes percutaneous arterial access unsafe;

8. High risk candidates of CAS defined as the Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST);

9. Thiazides taken within 14 days before randomization;

10. Participating in any other clinical trial that has not completed the required protocol follow-up period;